COMPUTATIONAL ANALYSIS OF GENOMIC CHARACTERIZATION AND DRUG RESPONSE AVAILABILITY IN CANCER CELL LINES FOR PERSONALIZED CANCER THERAPY
Abstract
Computational analysis of genomic characterization and drug response availability in cancer cell lines for personalized cancer therapy was conducted to evaluate the suitability of a cancer cell line dataset for descriptive pharmacogenomic research. The study analyzed 1001 cancer cell lines using variables related to cell line identity, genomic profiling, drug response availability, cancer classification, microsatellite instability status, screen medium, and growth properties. Genomic characterization was assessed through whole-exome sequencing, copy number alterations, gene expression,
methylation, and MSI status, while drug response was examined as an availability-based variable. Descriptive statistical methods were used to calculate frequencies and percentages for genomic data availability, drug response availability, cancer type distribution, tissue descriptors, MSI status, and culture characteristics. The results showed strong genomic coverage across the dataset, with most cell lines containing major molecular characterization variables. Drug response availability was also high, supporting the usefulness of the dataset for pharmacogenomic model selection. Integrated
analysis identified a large subset of cancer cell lines with both complete genomic characterization and drug response availability, indicating their relevance for future personalized therapy studies. The dataset also showed broad representation across cancer types and tissue groups. The main limitation was the absence of quantitative drug sensitivity measures such as IC50, AUC, or dose-response values. Overall, the dataset provides a useful foundation for computational oncology and personalized cancer therapy research.
Downloads
References
Adam, G., Rampášek, L., Safikhani, Z., Smirnov, P., Haibe-Kains, B., & Goldenberg, A. (2020). Machine learning
approaches to drug response prediction: challenges and recent progress. NPJ precision oncology, 4(1), 19.
Alipour, S. (n.d.). Genomics of Drug Sensitivity in Cancer (GDSC) [Data set]. Kaggle.
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer
statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a
cancer journal for clinicians, 74(3), 229-263.
Carli, F., Di Chiaro, P., Morelli, M., Arora, C., Bisceglia, L., De Oliveira Rosa, N., ... & Raimondi, F. (2025). Learning
and applying general principles of cancer cell drug sensitivity. Nature Communications, 16(1), 1654.
Feng, F., Shen, B., Mou, X., Li, Y., & Li, H. (2021). Large-scale pharmacogenomic studies and drug response
prediction for personalized cancer medicine. Journal of Genetics and Genomics, 48(7), 540-551.
Greco, L., Rubbino, F., Dal Buono, A., & Laghi, L. (2023). Microsatellite instability and immune response: from
microenvironment features to therapeutic actionability—lessons from colorectal cancer. Genes, 14(6), 1169.
Kurilov, R., Haibe-Kains, B., & Brors, B. (2020). Assessment of modelling strategies for drug response prediction in
cell lines and xenografts. Scientific reports, 10(1), 2849.
Li, Y., Guo, Z., Gao, X., & Wang, G. (2023). Mmcl-cdr: enhancing cancer drug response prediction with multi-omics
and morphology images contrastive representation learning. Bioinformatics, 39(12), btad734.
Liu, Q., Hu, Z., Jiang, R., & Zhou, M. (2020). DeepCDR: a hybrid graph convolutional network for predicting cancer
drug response. Bioinformatics, 36(Supplement_2), i911-i918.
Masina, R., & Caldas, C. (2024). Precision Cancer Medicine 2.0—Oncology in the postgenomic era. Molecular
Oncology, 18(9), 2065-2069.
Mechahougui, H., Gutmans, J., Colarusso, G., Gouasmi, R., & Friedlaender, A. (2024). Advances in personalized
oncology. Cancers, 16(16), 2862.
Partin, A., Brettin, T. S., Zhu, Y., Narykov, O., Clyde, A., Overbeek, J., & Stevens, R. L. (2023). Deep learning methods
for drug response prediction in cancer: predominant and emerging trends. Frontiers in medicine, 10, 1086097.
Riedl, J. M., Moik, F., Esterl, T., Kostmann, S. M., Gerger, A., & Jost, P. J. (2024). Molecular diagnostics tailoring
personalized cancer therapy—an oncologist’s view. Virchows Archiv, 484(2), 169-179.
Sharifi-Noghabi, H., Jahangiri-Tazehkand, S., Smirnov, P., Hon, C., Mammoliti, A., Nair, S. K., ... & Haibe-Kains, B.
(2021). Drug sensitivity prediction from cell line-based pharmacogenomics data: guidelines for developing machine
learning models. Briefings in bioinformatics, 22(6), bbab294.
Sharma, A., Lysenko, A., Boroevich, K. A., & Tsunoda, T. (2023). DeepInsight-3D architecture for anti-cancer drug
response prediction with deep-learning on multi-omics. Scientific reports, 13(1), 2483.
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer
statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a
cancer journal for clinicians, 71(3), 209-249.
Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2020). Review of precision cancer medicine:
Evolution of the treatment paradigm. Cancer treatment reviews, 86, 102019.
Wang, C., Lye, X., Kaalia, R., Kumar, P., & Rajapakse, J. C. (2021). Deep learning and multi-omics approach to
predict drug responses in cancer. BMC bioinformatics, 22(Suppl 10), 632.
Xia, F., Allen, J., Balaprakash, P., Brettin, T., Garcia-Cardona, C., Clyde, A., ... & Stevens, R. (2022). A cross-study
analysis of drug response prediction in cancer cell lines. Briefings in bioinformatics, 23(1), bbab356.
Yu, G., & Fan, Q. (2025). Deep learning-driven drug response prediction and mechanistic insights in cancer
genomics. Scientific Reports, 15(1), 20824.
Yuan, R., Chen, S., & Wang, Y. (2020). Computational prediction of drug responses in cancer cell lines from cancer
omics and detection of drug effectiveness related methylation sites. Frontiers in Genetics, 11, 917
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 International Journal For Research In Biology & Pharmacy
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
In consideration of the journal, Green Publication taking action in reviewing and editing our manuscript, the authors undersigned hereby transfer, assign, or otherwise convey all copyright ownership to the Editorial Office of the Green Publication in the event that such work is published in the journal. Such conveyance covers any product that may derive from the published journal, whether print or electronic. Green Publication shall have the right to register copyright to the Article in its name as claimant, whether separately
or as part of the journal issue or other medium in which the Article is included.
By signing this Agreement, the author(s), and in the case of a Work Made For Hire, the employer, jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere, and is not being considered for publication elsewhere in any form, except as provided herein. Each author’s signature should appear below. The signing author(s) (and, in
